medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2020, Number 3

<< Back Next >>

Neumol Cir Torax 2020; 79 (3)

SARS-CoV-2: a bibliographic review of the most relevant topics and evolution of medical knowledge about the disease

Vargas-Lara AK, Schreiber-Vellnagel V, Ochoa-Hein E, López-Ávila A

Language: Spanish
References: 41
Page: 185-196
PDF size: 404.16 Kb.


ABSTRACT

Since December 2019 the world has been affected by a pandemic caused by the SARS-CoV-2 virus, which belongs to the β-coronavirus family. This group of viruses are known for their great infectious capacity, rapid transmission and clinical manifestation as a respiratory syndrome, which has caused the death of more than 300,000 people worldwide. This document was written from March to May 2020 in order to report of the most relevant issues of the disease; historical background, viral morphology, pathophysiology, transmission, clinical manifestations, clinical characteristics of infected patients and asymptomatic patients, incubation period, diagnostic tests, expected results in laboratory and imaging tests, main complications of infection, status of vaccine development and the use of convalescent plasma in treatment, development of a vaccine, prevention and personal care to avoid infection and, at last, possible reinfection. In addition, this article compares and verifies the information between various articles on each subtopic, to have a broad and complete perspective of the different results, findings and opinions about COVID-19.


REFERENCES

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):597-506. Available in: https://doi.org/10.1016/S0140-6736(20)30183-5

  2. Fehr AR, Perlman S. Coronavirus: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23. Available in: https://doi.org/10.1007/978-1-4939-2438-7_1

  3. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. Available in: https://doi.org/10.1186/s40249-020-00646-x

  4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. Available in: https://doi.org/10.1056/nejmoa2001017

  5. Solís A. Confirman primer positivo de coronavirus Covid-19 en México. Forbes Staff [en línea]. 28 febrero 2020. [Fecha de consulta 30 de mayo de 2020] Accesible en: https://www.forbes.com.mx/confirman-el-primer-caso-de-coronavirus-covid-19-en-mexico/

  6. Gobierno de la Ciudad de México. Situación actual Covid-19 CDMX (2020) [en línea]. [Fecha de consulta 30 de mayo de 2020] Accesible en: https://datos.cdmx.gob.mx/pages/covid19/?gclid=CjwKCAjwiMj2BRBFEiwAYfTbCpGrk95qVjrIIZffykcTU-jJYcKJarwfG2jjUTGeWtzlQofxnv3ahxoCheQQAvD_BwE

  7. World Health Organization. Coronavirus (COVID-19) events as they happen [Internet]. [Access date 2020 April 28] Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

  8. Perlman S. Anorher decade, another coronavirus. N Engl J Med. 2020;382(8):760-762. Available in: https://doi.org/10.1056/nejme2001126

  9. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16(3):240-246. Available in: https://doi.org/10.1007/s12519-020-00345-5

  10. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;13(1):11. Available in: https://doi.org/10.1186/s40779-020-00240-0

  11. Guana ME, Bernava JL. Recomendaciones diagnósticas y terapéuticas ante la respuesta inmune trombótica asociada a Covid-19 [en línea]. [Fecha de consulta 1 de mayo de 2020] Accesible en: https://fundacionio.com/wp-content/uploads/2020/04/Si%CC%81ndrome-RITAC.pdf.pdf.pdf.pdf.pdf.pdf.pdf

  12. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID- 19 and the possibility of fecal transmission. Aliment Pharmacol Ther. 2020;51(9):843-851. Available in: https://doi.org/10.1111/apt.15731

  13. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS- CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-1567. Available in: https://doi.org/10.1056/nejmc2004973

  14. Okhuese AV. Estimation of the probability of reinfection with COVID-19 by the susceptible-exposed-infectious-removed-undetectable-susceptible model. JMIR Public Health Surveill. 2020;6(2):e19097. Available in: https://doi.org/10.2196/19097

  15. Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci. 2020;35(18):e174. Available in: https://doi.org/10.3346/jkms.2020.35.e174

  16. Pérez-Suárez B, Martínez-Menchon T, Cutillas-Marco E. Hallazgos cutáneos en la pandemia de COVID-19 en la Región de Murcia (carta al editor). Med Clin (Barc). 2020;155(1):41-42. Disponible en: https://doi.org/10.1016/j.medcli.2020.05.001

  17. Fu B, Fu X. Clinical characteristics of 11 asymptomatic patients with COVID-19. Med Clin (Barc). 2020;155(2):87-88. Available in: https://doi.org/10.1016/j.medcli.2020.04.013

  18. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. Available in: https://doi.org/10.1016/j.jaut.2020.102433

  19. Gennaro FD, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, et al. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int J Environ Res Public Health. 2020;17(8):2690. Available in: https://doi.org/10.3390/ijerph17082690

  20. Massachusetts General Hospital. 2020 [en línea]. [Fecha de consulta 1 de mayo de 2020]. Accesible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/aspectos-hematol%C3%B3gicos-durante-el-COVID-19.pdf

  21. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng Vincent CC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with Coronavirus 2019 (COVID-19). Clin Infect Dis. 2020: ciaa478. Available in: https://doi.org/10.1093/cid/ciaa478

  22. Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO). 2020 [online]. [Access date 2020 09 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04330690?term=Remdesivir&recrs=ade&cond=COVID&draw=2&rank=6

  23. The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients. 2020 [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04321616?term=Remdesivir&recrs=ade&cond=COVID&draw=2&rank=7

  24. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684. Available in: https://doi.org/10.1016/s0140-6736(20)30361-5

  25. Corticosteroids during Covid-19 Viral pneumonia related to SARS-CoV-2 infection (CORTI-Covid). 2020 [online]. [Access date 2020 Jun 10] Available from: https://clinicaltrials.gov/ct2/show/NCT04344288?term=corticosteroids&cond=COVID-19&draw=2&rank=2

  26. Early Short Cpurse Corticosteroids in COVID-19. 2020 [online]. [Access date 2020 Jun 10] Available from: https://clinicaltrials.gov/ct2/show/study/NCT04374071?term=corticosteroids&cond=COVID-19&draw=2&rank=8

  27. Efficacy and Safety of Corticosteroids in COVID-19. 2020 [online]. [Access date 2020 Jun 10] Available from: https://clinicaltrials.gov/ct2/show/NCT04273321?term=corticosteroids&cond=COVID-19&draw=2&rank=6

  28. Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04377620?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=1

  29. Phase 3 Randomized, Doble-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Assiciated Cytokine Storm (RUXCOVID)(RUXCOVID) [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04362137?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=2

  30. Treatment of SARS Caused by COVID-19 With Ruxolitinib [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04334044?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=3

  31. Study of Ruxolitinib Plus Simvastatina in the Prevention and Treatment of Respiratory Failure of COVID-19. (Ruxo-Sim-20) [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04348695?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=6

  32. Plested E. Investigating a vaccine against COVID-19. 2020. Available in: https://doi.org/10.1186/ISRCTN90906759

  33. A phase I/II clinical trial for inactivated novel coronavirus (2019-CoV) vaccine (Vero cells). Chictr.org.cn. 2020 [online]. [Access date 2020 May 31] Available from: http://www.chictr.org.cn/showproj.aspx?proj=53003

  34. Use of convalescent plasma in the treatment of patients with severe COVID-19 pneumonia. En.irct.ir. 2020 [online]. [Access date 2020 May 31] Available from: https://en.irct.ir/trial/47266

  35. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang G, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38-43. Available in: https://doi.org/10.1093/infdis/jiaa228

  36. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561-1562. Available in: https://doi.org/10.1001/jama.2020.4940

  37. Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. J Med Virol. 2020. Available in: https://doi.org/10.1002/jmv.25870

  38. Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol. 2020;127:104358. Available in: https://doi.org/10.1016/j.jcv.2020.104358

  39. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence [published online ahead of print, 2020 Apr 9]. J Med Virol. 2020;10.1002/jmv.25855. Available in: https://doi.org/10.1002/jmv.25855

  40. Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69(6):599-606. Available in: https://doi.org/10.1007/s00011-020-01342-0

  41. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020;133(9):1039-1043. Available in: https://doi.org/10.1097/cm9.0000000000000774




2020     |     www.medigraphic.com